Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

NASDAQ:BOLT

Overview | Financials
Company Name Bolt Biotherapeutics, Inc.
Symbol BOLT
Currency USD
Price 0.638
Market Cap 24,412,942
Dividend Yield 0%
52-week-range 0.545 - 1.56
Industry Biotechnology
Sector Healthcare
CEO Dr. Randall C. Schatzman Ph.D.
Website https://www.boltbio.com

An error occurred while fetching data.

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with

Related Stocks

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

1.28 USD

SCYNEXIS, Inc. logo

SCYNEXIS, Inc.

SCYX

1.51 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.272 USD

Seelos Therapeutics, Inc. logo

Seelos Therapeutics, Inc.

SEEL

1.28 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Financials

Numbers are in millions USD

Numbers are in millions USD